Buy These 2 Stocks to Access China's Huge Healthcare Market
China spent $137 billion on healthcare in 2018 and could spend up to $170 billion annually by 2023. Two exciting biotech companies, BeiGene (NASDAQ: BGNE) and Zai Lab (NASDAQ: ZLAB), allow investors an opportunity to get in on the action while it's still early.
And why wouldn't you? Both companies have products already on the market, they have new drugs awaiting approval from Chinese regulators, and they're investing in promising R&D. Add in a multitude of pharmaceutical and biotech partnerships and well-known institutional investors, and everyday investors get an opportunity to invest alongside some of the most prominent names in the industry.
Image source: Getty Images.
Source Fool.com
